Complications of Biologic Therapy for Pediatric Cancer – What the Surgeon Needs to Know
sciencedirect.com shows its articles on its own site.
Read the article on sciencedirect.com ↗Article · Dec 2019 · 1 min read
In brief
In brief
This review examines surgical complications arising from biologic cancer therapies in pediatric patients, including direct effects like GI perforation and pneumothorax, as well as indirect impacts on wound healing. Surgeons must recognize these risks when biologic agents are integrated into multimodal treatment plans.
Written by the GCMD Library team from the article.
Publication date: Available online 20 November 2019
Source: Seminars in Pediatric Surgery
Author(s): Marcus M. Malek
Abstract
Biologic therapy for pediatric cancer has gained much enthusiasm over the past two decades.
Recent advances in the clinical sequencing of tumors, has also allowed for the identification of targetable mutations. These findings have created a new avenue of biologic agent development and study. As experience with biologic agents builds, so too must the awareness of the surgeon to identify potential complications of these drugs. Complications can result from the direct effect of a biologic on the patient, such as gastrointestinal perforation or secondary spontaneous pneumothorax, or they can be related to the effect a biologic has on another aspect of a patient's care, such as wound complications following surgery. The morbidity caused by these complications must be weighed against any potential benefit of an agent, when determining the role for biologic therapy in the overall cancer treatment strategy.